# Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio Vaccine

> **NCT01457560** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 80 (actual)

## Conditions studied

- Hepatitis B
- Acellular Pertussis
- Haemophilus Influenzae Type b
- Diphtheria
- Tetanus
- Poliomyelitis

## Interventions

- **BIOLOGICAL:** DTPa-HBV-IPV/Hib (Infanrix hexa™)
- **BIOLOGICAL:** OPV

## Key facts

- **NCT ID:** NCT01457560
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-02
- **Primary completion:** 2001-04
- **Final completion:** 2001-04
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2016-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01457560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01457560, "Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio Vaccine". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01457560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*